



Background: Nonalcoholic fatty liver disease (NAFLD) is associated with the increased burden of kidney. However, there is still no large population 
study to explore the potential relationship between NAFLD and mild kidney function damage (MKFD) after adjusted for confounding factors. This 
study is to test the hypothesis that NAFLD is associated with MKFD under controlling the eff ects of confounding factors.
Materials and methods: Levels of serum fasting glucose, creatinine, cholesterol, triglyceride, alanine aminotransferase and aspartate aminotran-
sferase were analyzed from 1412 Chinese Han adults. Questionnaire and physical examination were performed to explore the potential association 
of NAFLD with kidney function.
Results: NAFLD was associated with impairment of kidney function. Multivariate-adjusted odds ratio illustrated that, compared to subjects with 
normal liver, NAFLD subjects had a signifi cantly higher risk of MKFD with or without adjusted for blood glucose and other covariates (P = 0.041). 
Further results from multi-interaction analysis demonstrated that the underlying mechanisms linked NAFLD with impaired kidney function may be 
that they share common risk factors and similar pathological processes.
Conclusions: The most striking fi nding of this study is that NAFLD is negatively associated with kidney function, in nondiabetic population. NAFLD 
and MKFD may share similar risk factors and/or pathological processes.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a patho-
logical condition similar to alcohol-induced liver 
damage, while in the absence of alcohol abuse. It 
encompasses a wide spectrum liver injury ranging 
from simple steatosis, steatohepatitis, advanced fi -
brosis to cirrhosis, and has appeared as a world-
wide public health problem with a growing inci-
dence and prevalence (1-3). The estimated preva-
lence of NAFLD is 20% to 30% in adults, 2.6 to 10% 
in children and 75% in obese and diabetic (1-3).
Outcomes of NAFLD include, not only the devel-
opment and progression of chronic liver diseases 
(3,4), but also the risk enhancement of developing 
cardiovascular diseases and diabetes mellitus (5,6). 
Current evidences suggest that NAFLD is positively 
correlated with the morbidity and mortality of 
many liver complications including hepatocellular 
carcinoma (3,4). Though diagnosis of NAFLD is in-
suffi  cient to predict cardiovascular disease (7), in-
creased NAFLD is associated with an enhanced risk 
of incident cardiovascular disease (5). Moreover, 
the leading cause of death in patients with NAFLD 
is cardiovascular disease, and both NAFLD and car-
diovascular disease share similar risk factors and 
treatment strategies (5,8,9).
In recent years, there is abundant evidence for the 
potential links between NAFLD and kidney func-
tion. A series of cross-sectional studies indicate 
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that NAFLD, diagnosed by either ultrasonography, 
liver enzymes or biopsy, is independently associ-
ated with an increased risk of chronic kidney dis-
ease (CKD) (10-14). Some prospective studies also 
display that NAFLD, especially with elevated gam-
ma-glutamyl transferase concentration, contrib-
utes to CKD development (15,16). Intriguingly, ac-
cording to the National Kidney Foundation Prac-
tice Guidelines (17,18), mild kidney function dam-
age (MKFD) occurs early before CKD appearance, 
and the adverse outcomes of CKD may be prevent-
ed or delayed if MKFD can be detected and treat-
ed in time. In this context, MKFD is more important 
than CKD in health care. However, there is still no 
large population study to explore the potential re-
lationship between NAFLD and MKFD after adjust-
ed for blood glucose and other confounding fac-
tors.
For these reasons, we tested the hypothesis that 
NAFLD is associated with MKFD under controlling 
the eff ects of confounding factors, including age, 
gender, lifestyle factors, blood glucose, blood lip-
ids, and serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST). As a result, se-
rum levels of above-mentioned factors were ana-
lyzed from the volunteers, and questionnaire and 
physical examination were performed to explore 




NaCl, Na2HPO4 and other common used reagents 
(analytical grade) were from Sangon Biotech Co. 
Ltd., (Shanghai, China). Water was produced using 
a Milli-Q Plus purifi cation system (Millipore, Bed-
ford, MA).
Participants and questionnaire
The study was approved by the Institutional Re-
view Board of Hunan Normal University. All volun-
teers signed informed consent forms before their 
inclusion in the project.
From April 2009 to December 2010, a consecutive 
unselected recruitment was applied to recruit the 
subjects from those attending our institution. The 
total study subjects consisted of 2169 Chinese Han 
adults of both genders living in the urban area of 
Changsha City in the Central Region of China. Af-
ter excluded the subjects missing covariate data, 
with hepatitis, autoimmune responses, metabolic 
or hereditary factors or serum levels of fasting glu-
cose higher than 6.10 mmol/L, or with drugs or 
toxins, 1412 adults were included in analysis. The 
basic characteristics of the participants are shown 
in Table 1.
The questionnaire recorded information on demo-
graphics (age and gender), lifestyle habits (sleep, 
smoking history, drinking history and physical ac-
tivity), and detailed medical history. The question-
naire included fi ve possible aspects for sleep qual-
ity: well, insomnia, dreaminess, restless sleep, and 
other problems. Subjects were not classifi ed into 
sleep with some problems only when the answer 
was sleep well. The questionnaire for smoking his-
tory included fi ve possible aspects: never smoking, 
sometimes smoking, frequently smoking, stop 
smoking for less than 1 month and stop smoking 
for more than 1 month. Subjects were not classi-
fi ed into smoking only when the answer was never 
smoking or stop smoking for more than 1 month. 
The questionnaire for drinking history included 
four possible aspects: never drinking, average 
drinking per week for bear is __ cup or __ bottle, 
average drinking per week for wine is __ cup or __ 
bottle, and/or average drinking per week for liquor 
is __ cup or __ bottle. Subjects were not classifi ed 
into drinking only when the answer was never 
drinking. The questionnaire for physical activity in-
cluded four possible aspects: never participating 
exercise, participating exercise for ≤ 1 h/week, 1-3 
h/week or >3 h/week.
Blood sampling
Blood samples (5 mL) from the median cubital vein 
on the inside of the elbow were collected into va-
cutainer tubes (Becton Dickinson Medical Devices 
Co Ltd, Shanghai, China) containing K3-EDTA, ac-
cording to standard blood collection procedures 
(19,20), and stored at 0-4 °C. All detections were 
carried out within 8 h of sampling.
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(N = 861) (N = 551)
Age (years) 37 (19-69) 52 (20-91) <0.001
Gender, male, N (%) 508 (59.00%) 393 (71.32%) <0.001
BMI (kg/m2) 23.61 ± 3.37 24.24 ± 3.16 0.001
SBP (mmHg) 120.66 ± 14.14 127.31 ± 16.27 <0.001
DBP (mmHg) 74.38 ± 11.07 77.10 ± 11.62 <0.001
Glucose (mmol/L) 4.75 ± 0.46 4.86 ± 0.45 <0.001
Total cholesterol (mmol/L) 4.43 ± 0.86) 4.53 ± 0.76) 0.041
Triglyceride (mmol/L) 1.50 ± 1.17 1.75 ± 1.18 <0.001
ALT (U/L) 29.31 ± 22.30 26.69 ± 19.54 0.024
AST (U/L) 23.09 ± 10.02 23.32 ± 8.99 0.658
Tobacco consumption, N (%) 358 (41.58%) 236 (42.83%) 0.040
Current alcohol intake, N (%) 418 (48.55%) 299 (54.26%) 0.061
Sleep quality, well, N (%) 507 (58.89%) 389 (70.60%) <0.001
Physical inactivity, N (%) 482 (55.98%) 236 (42.83%) <0.001
NKF - normal kidney function; MKFD - mild kidney function damage; BMI - body mass index; SBP - systolic blood pressure; 
DBP - diastolic blood pressure; ALT - alanine aminotransferase; AST - aspartate aminotransferase.
TABLE 1. Basic characteristics of participants.
Physical examination
Stature, body weight and body mass index (BMI) 
were detected using an ultrasonic body scale SK-
CK (Sonka Electronic Technologies Co. Ltd., Shen-
zhen, China). The BMI cut-off  point for overweight 
was 25 kg/m2, as advocated by the World Health 
Organization (21).
After resting for 30 min, each participant’s blood 
pressure was measured three times in the sitting 
position, with the right arm relaxed and well sup-
ported by a table, at an angle of 45◦ from the trunk, 
using an automatic electronic sphygmomanome-
ter (Ken2-BPMSP-1; Pengcheng Healthcare Prod-
ucts Co. Ltd., Shenzhen, China).
According to our previous study (22), blood lipids 
(serum total cholesterol and triglyceride), fasting 
glucose, kidney function (serum creatinine), and 
liver function (AST and ALT) were measured using 
a chromatographic enzymatic method in a MIND-
RAY automatic analyzer BS-40 (MINDRAY Co. Ltd., 
Shenzhen, China). Serum hepatitis B viral antigens 
and antibodies were detected by Microplate read-
er MR-96 (MINDRAY Co. Ltd., Shenzhen, China).
Based on the diagnosis and classifi cation of diabe-
tes mellitus provisional report of a WHO consulta-
tion (23), subjects with fasting glucose concentra-
tion over 6.1 mmol/L were excluded from the da-
taset.
According to the guidelines of the Chinese Society 
of Hepatology (24), the diagnosis of NAFLD was 
based on ultrasonic examination using a MINDRAY 
DP-9900 Plus Digital B/W Ultrasound System (MIN-
DRAY Co. Ltd., Shenzhen, China). In detail, the fol-
lowed fi ve items were examined by a professional 
physician: 1) diff use enhancement of near fi eld 
echo in the hepatic region (stronger than in the 
kidney and spleen region) and gradual attenua-
tion of the far fi eld echo; 2) unclear display of intra-
hepatic lacuna structure; 3) mild to moderate 
hepatomegaly with a round and blunt border; 4) 
color Doppler ultrasonography shows a reduction 
of the blood fl ow signal in the liver or it is even 
hard to display, but the distribution of blood fl ow 
is normal; 5) unclear or non-intact display of envel-
op of right liver lobe and diaphragm. The subject 
displayed item 1 and any one of items 2–4 was di-
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agnosed as mild degree of fatty liver; displayed 
item 1 and any two items of items 2–4 as moderate 
fatty liver; displayed items 1 and 5 and any two of 
items 2–4 as severe fatty liver.
The inclusion criteria for NAFLD were no history of 
drinking alcohol, or weekly ethanol intake < 140 g 
in males and < 70 g in females, and without other 
causes including hepatitis, autoimmune respons-
es, metabolic or hereditary factors, and drugs or 
toxins (3,24,25).
The estimated glomerular fi ltration rate (eGFR) was 
calculated from serum creatinine using the Chron-
ic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) formula (26). Based on eGFR, kidney 
function was categorized according to the Nation-
al Kidney Foundation Practice Guidelines (17,18): 
normal kidney function (eGFR ≥ 90 mL/min/1.73 
m2 and no proteinuria), MKFD (eGFR = 60–89 mL/
min/1.73 m2 or with proteinuria).
Statistical analysis
Results were expressed as a mean ± standard de-
viation (SD). Statistical analysis of data was done 
using predictive analytics software (PASW) statis-
tics 18.0 (SPSS Inc., Chicago, IL). Figures were drawn 
by Origin Pro 8.0 (OriginLab Corporation, North-
ampton, MA). As data showed a normal distribu-
tion, parametric statistical methods were used. For 
comparison of the groups (diff erent physical activ-
ity levels), one-way analysis of variance (one-way 
ANOVA) was performed. To assess signifi cant F-ra-
tios obtained by analysis of variance, the least sig-
nifi cant diff erence (LSD) or the Tamhan’s T2 post-
hoc test was used. The associations between 
NAFLD and eGFR levels were analyzed by Spear-
man partial correlation with or without adjusting 
for age and other covariates. The odds ratio (OR) 
and 95% confi dence interval (CI) of MKFD associ-
ated with diff erent NAFLD levels were examined 
using multinomial logistic regression (27) adjust-
ing for the potential confounding eff ects of age, 
gender, alcohol intake, tobacco consumption, 
sleep quality, physical activity, BMI, systolic blood 
pressure, diastolic blood pressure, blood glucose, 
and serum levels of cholesterol, triglyceride, ALT 
and AST. P-values less than 0.05 were considered 
statistically signifi cant.
Results
There were signifi cant diff erences in age and most 
factors of physical examination among the sub-
jects with normal kidney function and with MKFD 
(P < 0.001) (Table 1).
As indicated by eGFR, NAFLD was associated with 
impairment of kidney function (Figure 1). Further 
analysis from multinomial logistic regression also 
confi rmed this result. The trend of MKFD was posi-
tively associated with enhancing levels of NAFLD 
(multivariate-adjusted OR = 2.31, 95% CI = 1.04-
5.17, for moderate to severe NAFLD vs. normal liver, 
P for trend = 0.041) (Table 2). With or without ad-
justed for age, gender, alcohol intake, tobacco con-
sumption, sleep quality, physical activity, BMI, 
systolic blood pressure, diastolic blood pressure, 
blood glucose, and serum levels of cholesterol, 
triglyceride, ALT and AST, results did not substan-
tially change (Table 2).
Table 3 showed MKFD risk associated with NAFLD 
stratifi ed by diff erent covariates respectively. All 
values were adjusted for gender, age, and other 
covariates. As illustrated by adjusted OR, the over-
all trend was that the higher risk of MKFD occurred 
in the more serious NAFLD. Especially, in the sub-
Normal liver Mild NAFLD
NAFLD

















FIGURE 1. Association of NAFLD and eGFR. Indicated by means 
() and SE ( ) of eGFR levels according to normal liver subjects, 
mild NAFLD and moderate to severe NAFLD. NAFLD, nonalco-
holic fatty liver disease; eGFR, estimated glomerular fi ltration 
rate. As the P value for the test of homogeneity of variances 
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NAFLD OR (95%CI) OR* (95%CI) OR** (95%CI)
MKFD
Mild NAFLD 1.44 (1.13-1.82) 1.35 (1.06-1.71) 1.16 (0.80-1.68)
MS NAFLD 1.91 (1.13-3.23) 1.71 (1.01-2.91) 2.31 (1.04-5.17)
P = 0.015 P = 0.046 P = 0.041
N$ 861/551 861/551 861/551
NAFLD - nonalcoholic fatty liver disease; MKFD - mild kidney function damage; MS NAFLD - moderate to severe NAFLD; OR - 
odds ratio; CI - confi dence interval.
*adjusted for blood glucose level.
**adjusted for age, gender, alcohol intake, tobacco consumption, sleep quality, physical activity, BMI, systolic blood pressure, 
diastolic blood pressure, blood glucose level, and serum levels of cholesterol, triglyceride, ALT and AST.
N$, normal kidney function / mild kidney function damage
TABLE 2. The OR and adjusted OR of MKFD associated with diff erent NAFLD levels.
MKFD OR* (95%CI)
Factor Subgroup N$ Mild NAFLD MS NAFLD
Gender
male 335/367 1.01 (0.66-1.55) 2.21 (0.92-5.29)
female 137/287 1.73 (0.78-3.86) 3.46 (0.19-62.63)
Age (years)
<50 222/539 1.27 (0.79-2.05) 3.92 (1.50-10.24)
≥50 250/115 0.99 (0.53-1.86) 0.64 (0.15-2.68)
BMI (kg/m2)
<25 287/448 1.18 (0.69-2.03) 6.01 (0.49-73.19)
≥25 185/206 1.10 (0.64-1.90) 1.97 (0.74-5.20)
Alcohol intake
no 148/249 1.49 (0.71-3.10) 4.43 (0.88-22.43)
yes 285/383 0.92 (0.58-1.45) 1.77 (0.66-4.70)
Tobacco consumption
no 224/320 1.13 (0.61-2.07) 5.83 (1.28-26.45)
yes 215/323 1.07 (0.64-1.77) 1.22 (0.42-3.52)
Sleep quality
well 365/468 1.15 (0.75-1.78) 2.39 (0.98-5.84)
not too well 100/181 1.36 (0.61-3.03) 3.17 (0.29-34.59)
Physical activity
sedentary 228/450 1.33 (0.81-2.18) 6.09 (2.17-17.10)
activity 244/204 1.02 (0.55-1.86) 0.46 (0.11-1.89)
NAFLD - nonalcoholic fatty liver disease; MKFD - mild kidney function damage; MS NAFLD - moderate to severe 
NAFLD; OR - odds ratio; CI - confi dence interval
*adjusted for age, gender, alcohol intake, tobacco consumption, sleep quality, physical activity, BMI, systolic blood 
pressure, diastolic blood pressure, blood glucose level, and serum levels of cholesterol, triglyceride, ALT and AST.
N$, mild kidney function damage / normal kidney function.
TABLE 3. MKFD associated with NAFLD levels stratifi ed by gender, age, BMI, alcohol intake, cigarette smoking, sleep quality and aver-
age physical activity levels.
groups of age < 50 years (moderate to severe 
NAFLD versus normal liver OR = 3.92, 95% CI = 1.50-
10.24), without tobacco consumption (moderate to 
severe NAFLD vs. normal liver OR = 5.83, 95% CI = 
1.28-26.45) and sedentary (moderate to severe 
NAFLD vs. normal liver OR = 6.09, 95% CI = 2.17-
17.10), moderate to severe NAFLD resulted in statis-
tically signifi cant increase of risk for MKFD (Table 3).
To evaluate the correlation of NAFLD with covari-
ates, the levels of diff erent covariates were com-
pared among normal liver, mild NAFLD and mod-
erate to severe NAFLD. Results showed that NAFLD 
could induce statistically signifi cant changes in al-
most all covariates (Table 4). Intriguingly, signifi -
cant diff erences of the covariates showed similar 
trends between MKFD versus normal kidney func-
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(N = 948) (N = 404) (N = 60)
Age (years) 40 (19-91) 46 (23-83) <0.001 44 (23-75) 0.701
Gender, male, N (%) 518 (54.64%) 329 (81.44%) <0.001 54 (90.00%) <0.001
BMI (kg/m2) 22.53 ± 2.69 26.17 ± 2.50 <0.001 29.16 ± 3.07 <0.001
SBP (mmHg) 119.91 ± 14.84 129.46 ± 14.27 <0.001 134.55 ± 11.73 <0.001
DBP (mmHg) 72.78 ± 10.45 80.21 ± 10.94 <0.001 85.43 ± 12.14 <0.001
Glucose (mmol/L) 4.74 ± 0.44 4.89 ± 0.48 <0.001 4.99 ± 0.49 <0.001
Total cholesterol (mmol/L) 4.37 ± 0.80 4.66 ± 0.87 <0.001 4.79 ± 0.67 <0.001
Triglyceride (mmol/L) 1.29 ± 0.91 2.19 ± 1.36 <0.001 2.59 ± 1.55 <0.001
ALT (U/L) 23.11 ± 16.08 36.26 ± 23.78 <0.001 56.06 ± 34.13 <0.001
AST (U/L) 21.72 ± 7.79 25.53 ± 11.78 <0.001 30.34 ± 12.93 <0.001
Tobacco consumption, N (%) 362 (38.19%) 201 (49.75%) 0.380 31 (51.67%) 0.634
Current alcohol intake, N (%) 445 (46.94%) 237 (58.66%) 0.663 35 (58.33%) 0.886
Sleep quality, well, N (%) 579 (61.08%) 272 (67.33%) 0.358 45 (75.00%) 0.820
Physical inactivity, N (%) 471 (49.68%) 214 (52.97%) 0.488 33 (55.00%) 0.993
NAFLD - nonalcoholic fatty liver disease; MS NAFLD - moderate to severe NAFLD; BMI - body mass index; SBP - systolic blood pressure; 
DBP - diastolic blood pressure; ALT - alanine aminotransferase; AST - aspartate aminotransferase.
P value was calculated by compared to subjects with normal liver.
TABLE 4. Comparison of diff erent factors between subjects diagnosed as moderate to severe NAFLD, mild NAFLD versus normal liver
tion and moderate to severe NAFLD, mild NAFLD 
versus normal liver (Tables 1 and 4).
Discussion
Recently, it has been recognized that the growing 
prevalence of NAFLD imposes an increasing bur-
den on kidney, and contributes to CKD in these 
population with or without diabetes mellitus 
(10,11,15). All these studies are based on the cut-off  
point of eGFR ≤ 60 mL/min/1.73 m2 or with overt 
proteinuria for CKD. However, according to the Na-
tional Kidney Foundation Practice Guidelines 
(17,18), MKFD is more important than CKD in health 
care in that early detection and treatment of MKFD 
can prevent or delay the adverse outcomes of CKD. 
Therefore, aimed to explore the relationship be-
tween NAFLD and kidney function, we apply the 
cut-off  point of eGFR < 90 mL/min/1.73 m2 for 
MKFD.
This large population study showed that both mild 
NAFLD and moderate to severe NAFLD could sig-
nifi cantly suppress eGFR, an index of kidney func-
tion. In particular, the negative association be-
tween eGFR and NAFLD was achieved from the 
subjects without diabetes, and the correlation co-
effi  cient did not substantially change with or with-
out adjusted for blood glucose levels and other 
confounding factors. This fi nding is corroborated 
by the results from non-hypertensive and non-dia-
betic Korean men, illustrating an increased inci-
dence of CKD in NAFLD subjects (15,16). It seems 
that NAFLD can suppress kidney function in a dia-
betes-independent manner. Intriguingly, some 
cross-sectional studies show NAFLD contributes to 
CKD development in type 1 and type 2 diabetes 
(10,11). Therefore, a logical explanation for these 
results from diff erent population groups may be 
that both blood glucose and NAFLD are involved 
in impairing process of kidney function, while op-
erating modes are independent.
Though accumulated evidences support the rela-
tionship between NAFLD and CKD (10-16), the un-
derlying mechanisms linked NAFLD with CKD are 
still poorly understood. A plausibly speculative 
theory has been suggested that NAFLD and CKD 
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share many important common risk factors and 
similar pathological processes (28). In consistence 
with the hypothesis, our results indicate that many 
covariates, including age, gender, sleep quality, 
physical activity, BMI, blood pressure, blood glu-
cose, and serum concentration of total cholesterol, 
triacylglycerol, ALT and AST, show signifi cantly 
similar changes between MKFD versus normal kid-
ney function and NAFLD versus normal liver. How-
ever, whether NAFLD and CKD are merely coexten-
sive consequences of these risk factors, or NAFLD 
is a direct risk factor contributing to the damage of 
kidney function, it is still an open question at 
present. This may deserve further investigation to 
carefully determine the underlying mechanisms 
that contribute to the pathogenesis of CKD and 
NAFLD from molecular, animal and other model 
systems.
In conclusion, this is the fi rst study with specifi c 
goal for exploring the relationship between NAFLD 
and MKFD in population with normal blood glu-
cose levels. The most striking fi nding of this study 
is that NAFLD is negatively associated with kidney 
function, indicated by eGFR, in nondiabetes popu-
lation. The underlying mechanisms linked NAFLD 
with impaired kidney function may be common 
risk factors and similar pathological processes. The 
health care providers and the public should pay 
more attention to risk factor modifi cations to 
ameliorate NAFLD and improve kidney function.
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Nealkoholna bolest masne jetre povezana je s poremećajem funkcije bubrega 
kod nedijabetičke populacije
Sažetak
Uvod: Nealkoholna bolest masne jetre (engl. nonalcoholic fatty liver disease, NAFLD) povezana je s povećanim opterećenjem bubrega. Međutim, 
u populaciji još nije provedeno veliko istraživanje moguće povezanosti između NAFLD i blagog poremećaja funkcije bubrega (engl. mild kidney 
function damage, MKFD) uz kontrolu i prilagodbu zbunjujućih čimbenika.
Materijali i metode: Kod 1.412 muškarca Han Kineza analizirane su koncentracija glukoze natašte u serumu, koncentracije kreatinina, koleste-
rola, triglicerida te aktivnosti alanin-aminotransferaze i aspartat-aminotrasferaze. Ispitanici su ispunili upitnik te su prošli fi zički pregled kako bi 
se istražila potencijalna povezanost NAFLD s bubrežnom funkcijom.
Rezultati: NAFLD je povezana poremećajem funkcije bubrega. Omjer izgleda prilagođen za multivarijantnu analizu pokazuje da u usporedbi s 
ispitanicima s zdravom jetrom, ispitanici s NAFLD imaju značajno viši rizik od MKFD s (ili bez) prilagodbe za koncentraciju glukoze u krvi i druge 
kovarijanate (P = 0.041). Daljnji rezultati multi-interakcijske analize pokazali su da mehanizmi u podlozi koji povezuju NAFLD s poremećajem 
funkcije bubrega odaju da NAFLD i MKFD mogu imati zajedničke učestale čimbenike rizika i slične patološke procese.
Zaključak: Najupečatljiviji zaključak ovog istraživanja jest negativna povezanost NAFLD s funkcijom bubrega kod nedijabetičke populacije. Tako-
đer postoji mogućnost da NAFLD i MKFD imaju slične čimbenike rizika i/ili patološke procese.
Ključne riječi: nealkoholna bolest masne jetre (NAFLD); procjena brzine glomerularne fi ltracije (eGFR); blagi poremećaj funkcije bubrega 
(MKFD)
